Patents Assigned to Pfizer
  • N-Acylpyrrolidine Ether Tropomyosin-Related Kinase Inhibitors
    Publication number: 20160221989
    Abstract: The present invention relates to compounds of Formula I described herein and their pharmaceutically acceptable salts, and their use in medicine, in particular as Trk antagonists.
    Type: Application
    Filed: August 4, 2015
    Publication date: August 4, 2016
    Applicant: Pfizer Inc.
    Inventors: Sharanjeet Kaur Bagal, Kiyoyuki Omoto, Sarah Elizabeth Skerratt, Jingrong Jean Cui, Samantha Elizabeth Greasley, Indrawan James McAlpine, Asako Nagata, Sacha Ninkovic, Michelle Bich Tran-Dubé
  • USE OF ACETYL-COA CARBOXYLASE INHIBITORS FOR TREATING ACNE VULGARIS
    Publication number: 20160220557
    Abstract: The present invention relates to methods of treating and/or preventing acne in patients comprising the step of administering to patients in need of such treatment a therapeutically effective amount of an ACC inhibitor or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 29, 2014
    Publication date: August 4, 2016
    Applicant: Pfizer Inc.
    Inventors: William Paul Esler, Gabriele Elisabeth Sonnenberg
  • Vectors for expression of prostate-associated antigens
    Patent number: 9402901
    Abstract: The present disclosure provides (a) vectors comprising a multi-antigen construct encoding two, three, or more immunogenic PAA polypeptides; (b) compositions comprising the vectors, (c) methods relating to uses of the vectors and compositions for eliciting an immune response or for treating prostate cancers.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: August 2, 2016
    Assignee: Pfizer Inc.
    Inventor: Joseph John Binder
  • Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
    Patent number: 9403846
    Abstract: The present invention provides compounds of formula I, wherein the variables R1, R2, R5 and b are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: August 2, 2016
    Assignee: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Brian Thomas O'Neill, Christopher Ryan Butler, Erik Alphie LaChapelle
  • 2-thiopyrimidinones
    Patent number: 9399626
    Abstract: Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: July 26, 2016
    Assignee: Pfizer Inc.
    Inventors: Philip A. Carpino, Edward L. Conn, Robert L. Dow, Matthew S. Dowling, David Hepworth, Daniel Wei-Shung Kung, Suvi Orr, Benjamin N. Rocke, Roger B. Ruggeri, Matthew F. Sammons, Joseph S. Warmus, Yan Zhang
  • Dispensing device
    Patent number: 9399103
    Abstract: A device for dispensing individual doses of powder from respective pockets of a disc-shaped carrier by outwardly rupturing a lidding foil by means of pressure on an opposite side surface, the device providing individual respective deaggregation flow paths for each pocket, split airstreams allowing improved entrainment of powder, a cam mechanism for outwardly rupturing the pockets, an indexing mechanism linked to the cam mechanism and a dose counter.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: July 26, 2016
    Assignee: PFIZER LIMITED
    Inventors: Peter John Houzego, John Kelshaw Conway, Martin Douglas Pearl, Andrew Mark Bryant
  • Therapeutic Antibody
    Publication number: 20160207991
    Abstract: The present invention relates to antibodies that bind brain-derived neurotrophic factor (BDNF). The invention further relates to nucleic acid sequences coding for such antibodies. The present invention also relates to immunoconjugates comprising the antibodies of the invention and pharmaceutical compositions comprising the antibodies and/or the immunoconjugates. The present invention further relates to methods for treating pain and medical uses relating thereto.
    Type: Application
    Filed: September 1, 2015
    Publication date: July 21, 2016
    Applicant: PFIZER INC.
    Inventors: Laird Bloom, Qingcong Lin, Heather Hongrong Shih, Ying Sun, Orla Margaret Cunningham, William James Jonathan Finlay
  • SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR
    Publication number: 20160207953
    Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Application
    Filed: April 7, 2016
    Publication date: July 21, 2016
    Applicant: Pfizer Inc.
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
  • CRIZOTINIB FOR USE IN THE TREATMENT OF CANCER
    Publication number: 20160206608
    Abstract: The present invention relates to the use of ROS kinase inhibitors for treating abnormal cell growth in mammals. In particular, the invention provides methods of treating mammals suffering from cancer mediated by at least one genetically altered ROS. In particular, the invention provides methods of treating mammals suffering from cancer mediated by at least one genetically altered ROS by administration of crizotinib.
    Type: Application
    Filed: July 24, 2012
    Publication date: July 21, 2016
    Applicant: Pfizer Inc.
    Inventors: James Gail Christensen, Yahong Zou
  • Indole and indazole compounds that activate AMPK
    Patent number: 9394285
    Abstract: The present invention relates to indole and indazole compounds of Formula (I) that activate 5? adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: July 19, 2016
    Assignee: Pfizer Inc.
    Inventors: Samit Kumar Bhattacharya, Kimberly O'Keefe Cameron, Matthew Scott Dowling, David Christopher Ebner, David James Edmonds, Dilinie Prasadhini Fernando, Kevin James Filipski, Daniel Wei-Shung Kung, Esther Cheng Yin Lee, Aaron Christopher Smith, Meihua Mike Tu
  • HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS
    Publication number: 20160200711
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.
    Type: Application
    Filed: March 22, 2016
    Publication date: July 14, 2016
    Applicant: PFIZER INC.
    Inventors: DAVID LAWRENCE FIRMAN GRAY, LEI ZHANG, MICHALE AARON BRODNEY, MICHAEL ERIC GREEN, CHAKRAPANI SUBRAMANYAM
  • Oral Delivery Product
    Publication number: 20160199409
    Abstract: This invention provides a nutritional supplement composition which is a vitamin mint that can be taken anytime or anywhere without water or other liquid which is usually required for swallowing a tablet. The present invention is a nutritional supplement composition which is a convenient, flavorful and enjoyable vitamin mint which can be ingested without water.
    Type: Application
    Filed: January 13, 2016
    Publication date: July 14, 2016
    Applicant: Pfizer Inc.
    Inventors: Michael A. Goode, Anne Rehne Volke
  • Process for the preparation of voriconazole and analogues thereof
    Patent number: 9388167
    Abstract: The present invention provides a process for preparing a compound of formula: (Formula XI and XII) (XI) (XII) wherein X, Y, Z, A, B and E are as defined herein, by reacting a compound of formula: (Formula XIII) (XIII) with a compound of formula: (Formula XIV and XV) (XIV) (XV) respectively, in the presence of a transition metal catalyst, a ligand suitable for use with 15 the catalyst and a reducing agent. The invention also provides novel intermediates.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: July 12, 2016
    Assignee: Pfizer Ireland Pharmaceuticals
    Inventors: Adam James Musgrave Burrell, Padraig Mary O'Neill, Alan John Pettman
  • Anti-EFNA4 antibody-drug conjugates
    Patent number: 9381205
    Abstract: The present invention provides for anti-EFNA4 antibody-drug conjugates and methods for preparing and using the same.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: July 5, 2016
    Assignees: Pfizer, Inc., Stemcentrx, Inc.
    Inventors: Marc Isaac Damelin, Kiran Manohar Khandke, Puja Sapra, Alexander John Bankovich, Scott J. Dylla
  • ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR
    Publication number: 20160176851
    Abstract: Provided herein are antagonists of prostaglandin EP3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof.
    Type: Application
    Filed: December 16, 2015
    Publication date: June 23, 2016
    Applicant: Pfizer Inc.
    Inventors: Kevin Bahnck, Daniel Canterbury, David James Edmonds, Kentaro Futatsugi, Esther Cheng Yin Lee, Elnaz Menhaji-Klotz, Jana Polivkova, Robert Vernon Stanton
  • Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders
    Patent number: 9370516
    Abstract: The present invention relates to methods of treating sleep disorders in patients comprising administration of a ghrelin receptor inverse agonist or antagonist. The invention also includes methods of treating sleep disorders comprising the administration of a pharmaceutical composition comprising a ghrelin receptor inverse agonist or antagonist and at least one pharmaceutically acceptable carrier, diluent, or excipient.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: June 21, 2016
    Assignee: Pfizer Inc.
    Inventors: William S. Denney, Margaret Jackson, Gabriele Sonnenberg
  • Processes for the preparation of isothiazole derivatives
    Patent number: 9371298
    Abstract: Processes and intermediates for the preparation of compounds of the Formula I and the pharmaceutically acceptable salts, prodrugs, solvates and hydrates thereof, wherein R1, R2, and R3 have the definitions provided herein.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: June 21, 2016
    Assignees: Pfizer Inc., OSI Pharmaceuticals, LLC
    Inventors: David B. Damon, Brian P. Jones
  • COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INDUCING ANTIBODIES FOR THE TREATMENT OF CANCER
    Publication number: 20160152722
    Abstract: Methods for treating cancer in a patient in need thereof, with a therapeutically effective amount of an anti-4-1BB antibody in combination with a therapeutically effective amount of an ADCC-inducing antibody, are disclosed.
    Type: Application
    Filed: February 1, 2016
    Publication date: June 2, 2016
    Applicant: Pfizer Inc.
    Inventors: Leslie Lynne Sharp, Timothy Scott Fisher, Mark William Elliott
  • TREATMENT WITH ANTI-PCSK9 ANTIBODIES
    Publication number: 20160152734
    Abstract: The present invention concerns dosages for the treatment of human patients susceptible to or diagnosed with a disorder characterized by marked elevations of low density lipoprotein particles in the plasma with a PCSK9 antagonist antiboyd alone or in combination with a statin.
    Type: Application
    Filed: February 5, 2016
    Publication date: June 2, 2016
    Applicant: PFIZER INC.
    Inventor: Chandrasekhar UDATA
  • Adhesive heat patch
    Patent number: D762869
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: August 2, 2016
    Assignee: Pfizer Inc.
    Inventors: Robert F Beckman, Marina Belkin, Kristen Hejduk Brinkdopke, Mark Edward Fagan, Matthew Clifton Keller